NCT00682305View on ClinicalTrials.gov

Allogeneic Stem Cell Transplantation (SCT) With Treosulfan, VP-16 and Cyclophosphamid for Patients With Acute Lymphoblastic Leukemia (ALL)

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

January 31, 2013

Study Completion Date

August 31, 2013

Conditions
Acute Lymphoblastic Leukemia
Interventions
PROCEDURE

Hematopoietic stem cell transplantation

"conditioning regimen:~* day -7: 12g/m\^2 Treosulfan~* day -6: 12g/m\^2 Treosulfan~* day -5: 12g/m\^2 Treosulfan~* day -4: 30mg/kg BW Etoposide~* day -3: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~* day -2: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~* day -1: 20mg/kg ATG Fresenius (OPTIONAL)~* day 0: SCT"

Trial Locations (1)

20246

University Medical Center Hamburg-Eppendorf, Hamburg

All Listed Sponsors
lead

Universitätsklinikum Hamburg-Eppendorf

OTHER

NCT00682305 - Allogeneic Stem Cell Transplantation (SCT) With Treosulfan, VP-16 and Cyclophosphamid for Patients With Acute Lymphoblastic Leukemia (ALL) | Biotech Hunter | Biotech Hunter